title: Induction of cytochromes P450 in small intestine by chemopreventive compounds.
abstract: OBJECTIVE
  Since flavonoids and other natural compounds exert beneficial effects on human health, their consumption rapidly increases. However, they can modulate the activity of xenobiotic-metabolizing enzymes involved in activation and detoxification of food and environmental carcinogens. Thus, their potential negative effects should be examined.
  
  
  METHODS
  The induction effects of selected chemopreventive compounds, administered per orally by gastric gavages to rats, on cytochrome P450 (CYP) 1A and 2B were determined in liver and small intestine using Western blotting analysis and specific metabolic activity assays.
  
  
  RESULTS
  Comparing CYPs expression along small intestine, the highest induction was observed in the proximal part near pylorus with rapid decrease towards the distal part. In response to chemopreventive compounds, the marked induction of CYP1A and CYP2B in liver was observed after diallyl sulphide and flavone treatment. In small intestine, beta-naphthoflavone, diallyl sulphide and curcumin induced CYP1A1 and CYP2B1. In both tissues, resveratrol did not significantly affect CYPs expression. The results of Western blotting detection of CYPs correlate well with their specific enzymatic activities.
  
  
  CONCLUSIONS
  Presented data indicate ambiguous impact of chemopreventive compounds on cytochromes P450, main xenobiotic-metabolizing enzymes. Thus, the question of safety and unlimited consumption of these compounds arises.
authors.affiliation: Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic. jitus.k@atlas.cz
authors.forename: Jitka
authors.initials: J
authors.lastname: Krizkova
authors.forename: Kamila
authors.initials: K
authors.lastname: Burdova
authors.forename: Jiri
authors.initials: J
authors.lastname: Hudecek
authors.forename: Marie
authors.initials: M
authors.lastname: Stiborova
authors.forename: Petr
authors.initials: P
authors.lastname: Hodek
mesh_terms: D000498:Allyl Compounds / Q000494:pharmacology; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D003474:Curcumin / Q000494:pharmacology; D019363:Cytochrome P-450 CYP1A1 / Q000096:biosynthesis / Q000235:genetics; D019362:Cytochrome P-450 CYP2B1 / Q000096:biosynthesis / Q000235:genetics; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis*; D005419:Flavonoids / Q000494:pharmacology*; D007421:Intestine, Small / Q000201:enzymology*; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology; D013440:Sulfides / Q000494:pharmacology; D015262:Xenobiotics / Q000378:metabolism; D019324:beta-Naphthoflavone / Q000494:pharmacology
chemical_list: D000498:Allyl Compounds; D016588:Anticarcinogenic Agents; D005419:Flavonoids; D013267:Stilbenes; D013440:Sulfides; D015262:Xenobiotics; D019324:beta-Naphthoflavone; C038491:allyl sulfide; D003577:Cytochrome P-450 Enzyme System; D019363:Cytochrome P-450 CYP1A1; D019362:Cytochrome P-450 CYP2B1; D003474:Curcumin; D000077185:Resveratrol